Short Interest in Nanobiotix S.A. (NASDAQ:NBTX) Declines By 89.1%

Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report) saw a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 6,800 shares, a drop of 89.1% from the May 15th total of 62,300 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 10,900 shares, the short-interest ratio is presently 0.6 days.

Nanobiotix Trading Down 10.6%

NBTX stock traded down $0.61 during trading on Friday, hitting $5.15. 11,921 shares of the stock traded hands, compared to its average volume of 15,869. Nanobiotix has a one year low of $2.76 and a one year high of $6.00. The company has a 50 day simple moving average of $3.76 and a 200 day simple moving average of $3.49.

Hedge Funds Weigh In On Nanobiotix

Several institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in Nanobiotix in the 4th quarter valued at about $39,000. Jane Street Group LLC acquired a new stake in Nanobiotix in the 4th quarter valued at about $73,000. Geode Capital Management LLC acquired a new stake in Nanobiotix in the 4th quarter valued at about $29,000. Finally, OLD Mission Capital LLC acquired a new stake in Nanobiotix in the 4th quarter valued at about $139,000. 38.81% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on NBTX shares. Guggenheim cut their price target on shares of Nanobiotix from $12.00 to $8.00 and set a "buy" rating for the company in a report on Friday, April 4th. UBS Group raised shares of Nanobiotix to a "hold" rating in a report on Monday, February 17th.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.